Dr. Gregory C. Rigdon

• 
  ir.icagen.com/phoenix.zhtml?c=178443&p=irol-govBio&ID=1 - [Cached Version]
  Published on: 3/10/2007    Last Visited: 3/10/2007  

  Gregory C. Rigdon, Ph.D.Icagen - Corporate Governance - Biography
  ...
  Gregory C. Rigdon, Ph.D.Vice President, New Product Development
  
  Dr. Rigdon has been our vice president, new product development since 2001.From 1997 to 2001, Dr. Rigdon served as our director of new product development.From 1986 to 1997, Dr. Rigdon held several positions at Burroughs Wellcome Corp. and Glaxo Wellcome Corp., including most recently as project leader of an international product development team for a new anti-epileptic drug.Dr. Rigdon received his Ph.D. in pharmacology from the Texas Tech University Health Sciences Center and was awarded a National Research Council Research associateship at the United States Environmental Protections Agency.

• 
  ir.icagen.com/phoenix.zhtml?c=178443&p=irol-govManage - [Cached Version]
  Published on: 3/10/2007    Last Visited: 3/10/2007  

  Gregory C. Rigdon, Ph.D.Vice President, New Product Development

• 
  www.primenewswire.com/newsroom/news.html?d=137829 - [Cached Version]
  Published on: 3/10/2008    Last Visited: 3/11/2008  

  Greg Rigdon, Ph.D., Vice President, New Product Development, is scheduled to present a brief overview of Icagen's clinical product candidate, ICA-105665, as a potential treatment for epilepsy.

• 
  www.lead411.com/company.taf?_function=detail&Company_ui - [Cached Version]
  Published on: 3/4/2008    Last Visited: 4/1/2008  

  Gregory Rigdon [VCard] VP New Product Development

• 
  www.northcarolinalifescience.com/industry/facilities/di - [Cached Version]
  Published on: 8/29/2008    Last Visited: 8/29/2008  

  Gregory C. Rigdon, Ph.D., Vice President, New Product Development

• 
  www.biospace.com/news_story.aspx?NewsEntityId=66467 - [Cached Version]
  Published on: 8/14/2007    Last Visited: 8/15/2007  

  Participants will include P. Kay Wagoner, Ph.D., President and CEO; Richard D. Katz, M.D., SVP, Finance and Corporate Development, and Chief Financial Officer; Seth V. Hetherington, M.D., SVP Clinical and Regulatory Affairs; Douglas Krafte, Ph.D., Vice President of Biology and Pharmacology; Greg Rigdon, Vice President of New Product Development; and Mark Suto, Ph.D., Vice President of Chemistry.

• 
  ir.icagen.com/phoenix.zhtml?c=178443&p=irol-EventDetail - [Cached Version]
  Published on: 4/2/2006    Last Visited: 3/10/2007  

  Greg Rigdon, Ph.D, VP New Product Development

• 
  ASENT | 2007 Presentations - [Cached Version]
  Published on: 1/1/2007    Last Visited: 5/24/2009  

  Gregory C. Rigdon, Ph.D., Icagen, Inc.

• 
  Arrowhead Announces Agenda for 2nd Annual Pain... - [Cached Version]
  Published on: 8/10/2008    Last Visited: 8/18/2009  

  Gregory Rigdon, Ph.D., VP Product Development, Icagen

• 
  Epilepsy.com: Epilepsy drug candidate begins phase I... - [Cached Version]
  Published on: 1/16/2004    Last Visited: 5/10/2004  

  We are pleased to initiate our Phase I development program for ICA- 69673, said Greg Rigdon, PhD, vice president, new product development.Although there are several drugs on the market today for the treatment of epilepsy, many patients are not adequately treated with currently available therapies.By modulating a novel ion channel target, ICA-69673 has the potential to become an important additional therapeutic for the treatment of epilepsy and related disorders, said Rigdon.

Page:  1 2 3